Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

MorphoSys will buy Constellation for $1.7 billion

by Megha Satyanarayana
June 5, 2021 | A version of this story appeared in Volume 99, Issue 21

The structure of pelabresib.



MorphoSys, a German immunotherapy developer, has agreed to buy Constellation Pharmaceuticals in a deal valued at about $1.7 billion. Cambridge, Massachusetts–based Constellation specializes in epigenetic therapies for cancer. It has two experimental drugs in clinical trials: pelabresib, an inhibitor of bromodomain extraterminal motif proteins, and CPI-0209, an inhibitor of the histone methyltransferase EZH2. The deal is set to close in the third quarter.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.